Drugs affecting myometrial contractility in pregnancy.
D000818:Animals; D004874:Ergonovine / Q000009:adverse effects / Q000494:pharmacology*; D000431:Ethanol / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D005333:Fetus / Q000187:drug effects; D006801:Humans; D006908:Hydroxyprogesterones / Q000494:pharmacology; D007231:Infant, Newborn; D007751:Labor, Induced; D007743:Labor, Obstetric / Q000187:drug effects; D008755:Methylergonovine / Q000009:adverse effects / Q000494:pharmacology; D010121:Oxytocin / Q000009:adverse effects / Q000494:pharmacology*; D011247:Pregnancy; D011374:Progesterone / Q000009:adverse effects / Q000494:pharmacology; D011448:Prostaglandin Antagonists / Q000494:pharmacology; D011453:Prostaglandins / Q000009:adverse effects / Q000494:pharmacology*; D013268:Stimulation, Chemical; D013566:Sympathomimetics / Q000494:pharmacology; D014590:Uterine Contraction / Q000187:drug effects*
D006908:Hydroxyprogesterones; D011448:Prostaglandin Antagonists; D011453:Prostaglandins; D013566:Sympathomimetics; D000431:Ethanol; D011374:Progesterone; D010121:Oxytocin; D008755:Methylergonovine; D004874:Ergonovine